It began with a supplement and a promise, somewhere between TikTok wellness influencers, Bryan Johnson's age-hacking rituals, and shelf after shelf of taurine-charged energy drinks at your corner store, a straightforward question started generating buzz in the longevity sphere: Might taurine be the key to remaining young?

For biohackers, taurine became a superstar. Praised for its ability to enhance energy, enhance exercise performance, and even counteract age-related decline, this naturally occurring amino acid—found in meats, seafood, and yes, many energy drinks—was being touted as a possible "youth molecule." It was riding high on the popularity charts after a study in 2023 suggested that taurine supplementation could slow aging in animals. The implication? Maybe we're one step closer to unlocking the secret of human longevity.

A fresh and more comprehensive investigation has come forward to contradict such previous assertions, positing that taurine levels don't decline with age after all. In fact, they can stay the same—or even increase—well into adulthood. This has left health fans and scientists alike wondering: Have we been running after a false assumption all these years?

Before you add taurine to your anti-aging toolkit, it's time to go deep on what the science actually reveals. Is taurine really a secret to healthy aging—or just the latest in a series of overblown supplements?

While the quest to crack the code of longevity picks up speed around the world, taurine — a natural amino acid present in the body and in foods with high protein content — has been making waves as a possible anti-aging serum. From the labels of energy drinks to the regimes of biohackers, taurine is being touted as a molecule that promises to add years to your life and health to your years.

What is Taurine?

Taurine is not among the nine essential amino acids but plays an important role in a multitude of physiological processes. Taurine is present in the brain, heart, retina, and skeletal muscles and is involved in the formation of bile salts, fluid balance, nerve function, and antioxidant protection. It is produced by the body and also found in meat and shellfish, which are animal-based foods. It has become popular in the world of wellness over the years for its supposed benefits in increasing energy, improving cardiovascular function, and lowering inflammation.

Both energy drinks and certain supplements usually include taurine for its reported value in improved exercise function and clearer thinking. Although it is widely used, it has been largely agreed upon what the best level of taurine should be, and no official recommendations for daily intake are made in current dietary guidelines.

Interest in taurine's potential to slow or reverse aging was highest after an international 2023 study directed by scientists at the Rutgers New Jersey Medical School Healthy Longevity Program. The research discovered that levels of taurine decreased after midlife in animals and humans, and supplementation in mice, monkeys, and worms increased lifespan and enhanced indicators of well-being, such as muscle power and glucose metabolism.

This research was soon popular with biohackers such as Bryan Johnson, who added taurine to his supplement stack geared towards reversing biological age. Taurine was viewed as a nutrient that not only had a correlation with aging but worked against its effects. The expectation was that taurine had the potential to act as a biomarker of aging as well as a therapeutic target.

But new research released in Science on June 5, 2025, indicates the interconnection of taurine and aging might be more complex than imagined. A team of scientists headed by Dr. Luigi Ferrucci, scientific director at the National Institute on Aging (NIA), conducted a big-scale study using cross-sectional and longitudinal data — following more than 1,000 people aged 20-100 and several animal models.

Unlike the findings of the previous study, however, this new research determined that levels of taurine did not decrease with age. Instead, taurine levels in older subjects remained constant or even rose in older subjects from almost all cohorts, including rhesus macaque monkeys and mice. These findings are a far cry from previous assumptions that taurine is an effective biomarker for biological aging.

An important difference between the 2023 and 2025 reports is methodology. The previous research was very much based on cross-sectional data — comparing various people at one time point — whereas the new study included longitudinal analysis, following the same people over long times. Study co-author Maria Emilia Fernandez said that differences in taurine concentrations between people were far larger than any change with age. This discrepancy brings us to the question: Can taurine serve as a valid tool for measuring or impacting aging?

The group also investigated whether taurine was associated with health indicators such as muscle function, a known issue among aging individuals. Once more, the results indicated no uniform correlation between cohorts, further undermining the hypothesis that taurine concentrations are predictive of physical decline with age.

Also Read: This Common Energy Drink Ingredient Is Tied To Blood Cancer Risk

Potential Risks of Taurine Supplementation

Although taurine can yet possess therapeutic value under certain circumstances, it is not risk-free. Long-term or high-dose taurine supplementation has been associated with gastrointestinal upset, renal stress, and, in isolated instances, liver dysfunction or increased cancer risk, including leukemia. Such discoveries call for restraint, particularly among those who self-medicate taurine with the expectation of increasing lifespan.

Compounding the complexity, taurine levels are also known to vary according to conditions of health. Obesity patients tend to have taurine levels lower than normal, and protracted obesity can produce a taurine surge. Cancer patients produce increased levels in leukemia but reduced levels in breast cancer, indicating how subtle taurine's function in the body truly is.

Does Taurine Remain Promising?

Even with the recent setbacks to taurine's status as an anti-aging superhero, experts concede that it shouldn't be completely dismissed. Dr. Ferrucci believes that the conflicting results may even shed light on deeper mechanisms of aging. "The inconsistency can reveal some significant mechanisms with aging that may be new targets for treatments," he explained at a press conference.

Vijay Yadav, the principal investigator of the previous pro-taurine study, highlighted that the source and quality of data employed can influence results tremendously. He admits that further analysis and more refined clinical trials need to be conducted to determine how taurine could act with different biological systems in different populations.

So is taurine the fountain of youth? The answer is still out at this point. Early animal research had been promising a rosy picture, but recent evidence points to a more nuanced truth — one that's different for each person, species, and way of measuring. As with many supplements in the health space, the effect of taurine will probably depend on context, and more well-designed, human-specific research is necessary before it can be prescribed as a panacea anti-aging pill.

Meanwhile, people should consult doctors before adding taurine supplements to their regimen, particularly at high levels. Longevity research is being accelerated at a breakneck pace, yet where taurine is concerned, the tale is still in its early stages.

In June 2022, the U.S. Supreme Court issued a landmark decision in Dobbs v. Jackson Women’s Health Organization, overturning the 1973 Roe v. Wade ruling that had established a constitutional right to abortion. With the Dobbs ruling, the authority to regulate abortion returned to individual states—setting off a wave of legislative action that continues to reshape access to abortion care across the country.

Three years later, the national abortion landscape is more fragmented than ever. Some states have implemented near-total bans, while others have enshrined protections into their constitutions. As legal battles unfold and ballot measures continue to appear, access to abortion has become heavily dependent on geography.

tates That Ban and States That Protect

As of mid-2025, abortion is nearly banned in 13 states, with limited exceptions such as life endangerment or cases of rape or incest.

In over 25 other states, gestational limits range from six to 26 weeks. These restrictions are particularly concentrated in the South and Midwest, where legislative action following the Dobbs decision was swift.

Conversely, several states have moved to protect or expand abortion rights.

Since 2022, voters in California, Michigan, Ohio, and Vermont have passed constitutional amendments guaranteeing the right to abortion.

In states like Kansas, Kentucky, and Montana, voters rejected ballot measures that would have added new abortion restrictions.

In Missouri—a state that implemented one of the country’s strictest abortion bans immediately after the Dobbs ruling—voters passed a measure in 2024 to enshrine abortion access in the state constitution.

However, that decision was followed by further legal disputes. The Missouri Supreme Court later blocked abortion access again, and lawmakers have approved another referendum for 2026 that could reverse the constitutional amendment.

Increased Travel and Rising Costs for Abortion Seekers

As access has narrowed in certain states, more people are traveling long distances to obtain abortion care. According to data from The Brigid Alliance, an organization that provides travel and logistical support to abortion-seekers, average travel distances have increased nearly 50% since the Dobbs ruling. Today, many patients are traveling more than 1,400 miles round trip to reach a provider.

The group also reports that average travel-related expenses have risen to more than $2,300 per patient—reflecting the rising cost of transportation, lodging, and time away from work. The majority of their clients seeking assistance now come from states like Texas, Florida, Georgia, and North Carolina, where laws have become increasingly restrictive.

Southern states, in particular, have emerged as areas where abortion access is most limited. For example, Florida implemented a six-week abortion ban after a proposed constitutional amendment to protect abortion access narrowly failed, receiving just under the 60% threshold required for passage. This has redirected patients to other states with more permissive laws, such as Virginia.

Ballot Measures Shape State Policies

Since the Dobbs ruling, many abortion-related measures have appeared on state ballots—either to protect or restrict access. In 2024 alone, voters in Arizona, Colorado, Maryland, Missouri, Montana, Nevada, and New York took up initiatives involving abortion rights. Most successful measures focused on preserving access until fetal viability, generally considered to occur around 24 weeks of pregnancy.

Not all efforts to expand abortion rights have succeeded. In Nebraska, voters faced competing ballot measures—one aiming to restrict abortion after the first trimester (which passed) and another to guarantee abortion access up to fetal viability (which failed). South Dakota also rejected a measure to protect abortion rights.

Reflecting

Three years after Dobbs, the U.S. remains sharply divided on abortion access, with legal and political fights continuing to play out across state lines. As more ballot measures are introduced and court rulings evolve, the future of abortion rights in America remains uncertain—shaped less by federal law than by the individual choices of state governments and their voters.

A new study published in the Journal of the American Chemical Society offers critical insight into the biological mechanisms underlying type 2 diabetes. Researchers from the Indian Institute of Technology Bombay (IIT Bombay), in collaboration with IIT Kanpur and the Chittaranjan National Cancer Institute (CNCI), Kolkata, have identified a key trigger that accelerates the progression of this widespread disease: the structural protein collagen I.

A Rising Global Health Crisis

Type 2 diabetes currently affects over 500 million people worldwide, and numbers are expected to rise sharply in the coming decades. The disease is primarily driven by a combination of genetics, lifestyle factors, and complex cellular mechanisms. At its core lies the dysfunction of pancreatic β-cells, the insulin-producing cells responsible for regulating blood sugar levels.

As diabetes develops, β-cells either fail to produce enough insulin or the body’s cells become resistant to it. A lesser-known yet crucial hormone, amylin, is also secreted by these β-cells and plays a vital role in managing blood sugar after meals. However, in diabetic conditions, excessive amylin production leads to misfolding and toxic clumping, which damages β-cells and accelerates disease progression.

Collagen I Accelerates Amylin Clumping

In the latest study, the research team pinpointed fibrillar collagen I, a common component of the extracellular matrix, as a key factor driving the toxic aggregation of amylin. Found abundantly in connective tissues like skin and bones, collagen I is also present in the pancreatic environment—particularly in diabetic tissues where it is elevated.

“Every tissue is composed of cells and an extracellular matrix that provides structural support. In diabetic pancreatic tissue, this matrix, especially collagen I, becomes more prominent,” explained Prof. Shamik Sen, the study’s lead investigator from the Department of Biosciences and Bioengineering at IIT Bombay.

The researchers discovered that collagen I acts like a scaffold or platform, accelerating the misfolding and aggregation of amylin, which in turn damages β-cells. This discovery adds a new layer to understanding why the disease worsens over time, even with treatments targeting cellular pathways.

Biophysical Evidence Supports Findings

To investigate how collagen I interacts with amylin, the team used a suite of advanced biophysical tools. These included surface plasmon resonance to measure binding strength, atomic force microscopy to study molecular adhesion, thioflavin T fluorescence to track aggregation speed, and NMR spectroscopy to identify interacting regions of the molecules.

“Amylin almost coats the collagen fibres, forming stable, toxic aggregates that cells struggle to clear,” said Prof. Sen. The behavior of amylin on collagen fibres resembled trains moving on tracks—quickly and with destructive momentum.

Computer simulations by Prof. Prasenjit Bhaumik’s group at IIT Bombay confirmed that fibrillar collagen I accelerates the toxic aggregation process, offering further validation of the molecular interaction.

Biological Evidence from Mouse and Human Tissues

The team extended their study to biological samples from diabetic mice and humans. With the help of Prof. Hamim Zafar and Prof. Sai Prasad Pydi from IIT Kanpur, and Dr. Sankhadeep Dutta from CNCI, they analyzed single-cell data and tissue architecture.

The findings were striking: as diabetes progressed, both collagen and amylin levels rose, accompanied by damage to pancreatic islets—clusters of cells that house insulin-producing β-cells.

Testing the Combined Effect on Cells

To test the functional impact, the researchers grew lab-engineered β-cells on collagen gels containing amylin. These cells showed increased oxidative stress, reduced insulin production, and higher rates of cell death, compared to controls grown without collagen or amylin.

This suggests that the extracellular environment, particularly collagen I, plays a central role in worsening β-cell dysfunction in diabetes.

The findings could explain why many diabetes treatments fall short—they overlook the external microenvironment contributing to disease progression. “Unless we disrupt the interaction between amylin and collagen, we may not be able to eliminate the toxic pancreatic environment,” said Prof. Sen.

Looking ahead, the team is working on cryo-electron microscopy (cryo-EM) models to visualize how amylin and collagen interact at the molecular level. They are also exploring 3D tissue engineering strategies to restore pancreatic function by replicating healthy extracellular conditions.

A horror that bothers most transplant patients came true in the most weirdest way possible, two U.S. kidney transplant recipients were found to be infected with parasitic worms from a single deceased donor. The shocking revelation was documented in a case report published June 18 in the New England Journal of Medicine, shedding light on rare but severe donor-derived infections that may be slipping through existing screening protocols.

The source of the infections was traced back to a single deceased donor who had lived in the Caribbean, a region where some parasitic infections are more common. The donor’s kidneys were transplanted into two men at separate hospitals—Massachusetts General Hospital (MassGen) and Albany Medical Center—setting off a medical mystery that would take weeks to unravel.

The first recipient, a 61-year-old man, underwent surgery at MassGen. Ten weeks after the transplant, he was readmitted to the hospital with a cascade of alarming symptoms: nausea, vomiting, excessive thirst, abdominal and back pain, and fever. His condition deteriorated rapidly, with fluid building up in his lungs, a dramatic drop in oxygen levels, and eventually, respiratory failure and shock. Doctors in the intensive care unit noted a distinctive purple rash—like a constellation of bruises—spreading across his abdomen.

Dr. Camille Kotton, an expert in infectious diseases and transplants, led the investigation. She recalled previous cases of organ recipients being infected by Strongyloides stercoralis, a small roundworm commonly found in tropical and subtropical climates. Reaching out to New England Donor Services, the team discovered that the kidney donor—who had resided in the Caribbean—had indeed carried antibodies for Strongyloides, confirming prior exposure.

Testing of the recipient’s blood confirmed he had no preexisting antibodies for the parasite before the transplant but had developed them afterward. Further diagnostics revealed the worms had spread systemically, affecting his lungs, abdomen, and skin. The parasite had essentially colonized his entire body, exploiting his weakened immune defenses.

Further testing showed the patient had developed antibodies to the parasite post-transplant, and samples from his body revealed that the worms had spread to his abdomen, lungs, and skin.

How Rare Are Parasitic Infections in Transplants?

Infections from transplanted organs are exceedingly rare. Over more than a decade, only 14 out of every 10,000 organ transplants in the U.S. have resulted in donor-derived infections, according to a major review. Of these, parasitic infections—especially those caused by Strongyloides—account for a significant portion, but the overall numbers remain very low.

Historically, fewer than one in four U.S. organ procurement organizations regularly screened for Strongyloides. However, as awareness of these risks has grown, the Organ Procurement and Transplantation Network in 2023 called for universal testing for this parasite in all donors.

The discovery at MassGen prompted a nationwide alert to other centers that had received organs from the same donor. At Albany Medical Center, a 66-year-old man who had received the other kidney was experiencing fatigue, low white blood cell counts, and worsening kidney function. Armed with the new information, his doctors quickly diagnosed and treated the parasitic infection, preventing the severe complications seen in the first patient.

Why it is Important to Strengthen Safety Protocols?

This unsettling incident underscores the importance of rigorous donor screening, especially when donors have lived in regions where parasitic infections are more prevalent. The case has already prompted policy shifts and reinforced the need for continual vigilance in transplant medicine.

"Although donor-derived infections are uncommon, when they do occur, they can be catastrophic. We must use every tool available to prevent such outcomes," said Dr. Kotton.

These cases have prompted renewed calls for rigorous screening of organ donors, especially those from regions where certain parasites are endemic. While U.S. doctors already avoid using organs from donors with known active infections like tuberculosis, not all infectious agents are routinely tested for, and some, like Strongyloides, can remain dormant and undetectable for years.

Universal screening for Strongyloides is now being implemented, but experts caution that vigilance must remain high. Immunosuppressed patients—such as organ transplant recipients—are particularly vulnerable to rare infections, and symptoms can be easily mistaken for other complications like transplant rejection or drug reactions.

For patients awaiting transplants, the story may raise unsettling questions, but experts stress that the benefits of organ transplantation far outweigh the risks. The U.S. transplant system has an excellent safety record, and cases like these, while alarming, are extremely rare and now more preventable than ever.

Patients can play a role by staying informed, asking about donor screening protocols, and adhering closely to post-transplant care guidelines. As science and medicine evolve, so too does the capability to ensure safer, more effective transplants across the board.